Detalhes bibliográficos
| Resumo: | The emergence of novel variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) underscores the need to investigate alternative approaches to prevent infection and treat patients with coronavirus disease 2019. Here, we report the preclinical efficacy of NL-CVX1, a de novo decoy that blocks virus entry into cells by binding with nanomolar affinity and high specificity to the receptor-binding domain of the SARS-CoV-2 spike protein. Using a transgenic mouse model of SARS-CoV-2 infection, we showed that a single prophylactic intranasal dose of NL-CVX1 conferred complete protection from severe disease following SARS-CoV-2 infection. Multiple therapeutic administrations of NL-CVX1 also protected mice from succumbing to infection. Finally, we showed that infected mice treated with NL-CVX1 developed both anti-SARS-CoV-2 antibodies and memory T cells and were protected against reinfection a month after treatment. Overall, these observations suggest NL-CVX1 is a promising therapeutic candidate for preventing and treating severe SARS-CoV-2 infections. |
|---|
| Autores principais: | Rebelo, Maria |
|---|
| Outros Autores: | Tang, Cong; Coelho, Ana R; Labão-Almeida, Carlos; Schneider, Matthias M.; Tatalick, Laurie; Ruivo, Pedro; Pires de Miranda, Marta; Gomes, Andreia; Carvalho, Tânia; Walker, Matthew J.; Ausserwoeger, Hannes; Simas, J Pedro; Veldhoen, Marc; Knowles, Tuomas P. J.; Silva, Daniel-Adriano; Shoultz, David; Bernardes, Gonçalo J. L. |
|---|
| Assunto: | COVID-19 SARS-CoV-2 De novo protein decoys K18-hACE2 mice Treatment |
|---|
| Ano: | 2023 |
|---|
| País: | Portugal |
|---|
| Tipo de documento: | artigo |
|---|
| Tipo de acesso: | acesso aberto |
|---|
| Instituição associada: | Universidade de Lisboa |
|---|
| Idioma: | inglês |
|---|
| Origem: | Repositório da Universidade de Lisboa |
|---|